CDKN1B and endometrial carcinoma: Treatment with an AKT inhibitor rescues the mislocalization of p27 to the cytoplasm in endometrial carcinoma cells.18 The mislocalization of p27 has also been identified in other types of cancers,19–22 suggesting that sequestration of p27 in the cytoplasm might be an alternative way to inactivate p27-associated inhibitory activity in cancers.